JP Morgan Chase’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-184,000
| Closed | -$32.4M | – | 7545 |
|
|
2025
Q4 | $32.4M | Buy |
184,000
+34,000
| +23% | +$5.55M | ﹤0.01% | 1663 |
|
|
2025
Q3 | $21M | Buy |
+150,000
| New | +$20.3M | ﹤0.01% | 2056 |
|
|
2025
Q1 | – | Sell |
-99,000
| Closed | -$15.1M | – | 7343 |
|
|
2024
Q4 | $15.1M | Buy |
99,000
+80,000
| +421% | +$13.5M | ﹤0.01% | 2298 |
|
|
2024
Q3 | $3.68M | Hold |
19,000
| – | – | ﹤0.01% | 3452 |
|
|
2024
Q2 | $4.4M | Hold |
19,000
| – | – | ﹤0.01% | 3128 |
|
|
2024
Q1 | $4.1M | Sell |
19,000
-17,000
| -47% | -$3.98M | ﹤0.01% | 3266 |
|
|
2023
Q4 | $9.32M | Sell |
36,000
-8,700
| -19% | -$2.14M | ﹤0.01% | 2555 |
|
|
2023
Q3 | $11.5M | Buy |
44,700
+37,200
| +496% | +$9.95M | ﹤0.01% | 2138 |
|
|
2023
Q2 | $2.14M | Sell |
7,500
-6,100
| -45% | -$1.82M | ﹤0.01% | 3496 |
|
|
2023
Q1 | $3.78M | Sell |
13,600
-92,700
| -87% | -$25.6M | ﹤0.01% | 3035 |
|
|
2022
Q4 | $29.4M | Sell |
106,300
-145,400
| -58% | -$41.1M | ﹤0.01% | 1395 |
|
|
2022
Q3 | $67.2M | Buy |
251,700
+59,000
| +31% | +$12.5M | 0.01% | 907 |
|
|
2022
Q2 | $39.3M | Buy |
192,700
+82,500
| +75% | +$16.9M | 0.01% | 1176 |
|
|
2022
Q1 | $23.2M | Sell |
110,200
-9,100
| -8% | -$1.98M | ﹤0.01% | 1654 |
|
|
2021
Q4 | $28.6M | Buy |
119,300
+109,800
| +1,156% | +$28.2M | ﹤0.01% | 1518 |
|
|
2021
Q3 | $2.69M | Buy |
+9,500
| New | +$3.11M | ﹤0.01% | 3533 |
|
|
2021
Q2 | – | Sell |
-50,200
| Closed | -$14M | – | 6339 |
|
|
2021
Q1 | $14M | Sell |
50,200
-592,700
| -92% | -$160M | ﹤0.01% | 2053 |
|
|
2020
Q4 | $157M | Buy |
642,900
+587,800
| +1,067% | +$152M | 0.02% | 614 |
|
|
2020
Q3 | $15.6M | Buy |
55,100
+29,900
| +119% | +$8.34M | ﹤0.01% | 1678 |
|
|
2020
Q2 | $6.74M | Buy |
25,200
+21,500
| +581% | +$6.46M | ﹤0.01% | 2229 |
|
|
2020
Q1 | $1.17M | Sell |
3,700
-23,000
| -86% | -$6.98M | ﹤0.01% | 3308 |
|
|
2019
Q4 | $7.92M | Sell |
26,700
-71,500
| -73% | -$19.8M | ﹤0.01% | 2317 |
|
|
2019
Q3 | $22.9M | Buy |
98,200
+85,000
| +644% | +$19.8M | ﹤0.01% | 1488 |
|
|
2019
Q2 | $3.17M | Sell |
13,200
-97,200
| -88% | -$22.4M | ﹤0.01% | 3033 |
|
|
2019
Q1 | $26.1M | Sell |
110,400
-17,500
| -14% | -$5.51M | 0.01% | 1355 |
|
|
2018
Q4 | $38.5M | Buy |
127,900
+14,400
| +13% | +$4.6M | 0.01% | 1031 |
|
|
2018
Q3 | $40.1M | Buy |
113,500
+13,000
| +13% | +$4.48M | 0.01% | 1148 |
|
|
2018
Q2 | $29.2M | Buy |
100,500
+13,000
| +15% | +$3.65M | 0.01% | 1315 |
|
|
2018
Q1 | $24M | Sell |
87,500
-64,800
| -43% | -$20.1M | 0.01% | 1381 |
|
|
2017
Q4 | $48.5M | Buy |
152,300
+44,800
| +42% | +$14.4M | 0.01% | 997 |
|
|
2017
Q3 | $33.3M | Buy |
107,500
+43,570
| +68% | +$12.9M | 0.01% | 1168 |
|
|
2017
Q2 | $17.3M | Sell |
63,930
-1,602
| -2% | -$424K | ﹤0.01% | 1556 |
|
|
2017
Q1 | $17.9M | Buy |
65,532
+7,632
| +13% | +$2.16M | ﹤0.01% | 1542 |
|
|
2016
Q4 | $16.4M | Sell |
57,900
-26,472
| -31% | -$7.85M | ﹤0.01% | 1591 |
|
|
2016
Q3 | $26.4M | Buy |
84,372
+61,219
| +264% | +$18.1M | 0.01% | 1199 |
|
|
2016
Q2 | $5.6M | Sell |
23,153
-12,979
| -36% | -$3.42M | ﹤0.01% | 2214 |
|
|
2016
Q1 | $9.41M | Buy |
36,132
+13,232
| +58% | +$3.5M | ﹤0.01% | 1806 |
|
|
2015
Q4 | $7.01M | Buy |
+22,900
| New | +$6.58M | ﹤0.01% | 2020 |
|
|
2015
Q3 | – | Sell |
-1,071
| Closed | -$433K | – | 3919 |
|
|
2015
Q2 | $433K | Sell |
1,071
-23,929
| -96% | -$9.6M | ﹤0.01% | 3605 |
|
|
2015
Q1 | $10.6M | Hold |
25,000
| – | – | ﹤0.01% | 1869 |
|
|
2014
Q4 | $8.49M | Sell |
25,000
-7,262
| -23% | -$2.35M | ﹤0.01% | 2063 |
|
|
2014
Q3 | $10.7M | Buy |
+32,262
| New | +$10.6M | ﹤0.01% | 1870 |
|
Other funds holding BIIB
VCM
VPM
JP Morgan Chase's BIIB Position: Q1 2026 in Review
JP Morgan Chase increased its Biogen (BIIB) stake by 8.5% in Q1 2026, buying an estimated $29.3M and bringing the position to 2,016,009 shares worth $378M. The position accounts for 0.02% of the portfolio, ranked #484.
JP Morgan Chase first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.47B in Q1 2015. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- JP Morgan Chase held 2,016,009 shares of Biogen worth $378M as of Q1 2026.
- JP Morgan Chase bought 158,747 Biogen shares in Q1 2026, an estimated $29.3M.
- Biogen made up 0.02% of JP Morgan Chase's portfolio in Q1 2026, its #484 holding.
- JP Morgan Chase first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
- JP Morgan Chase's Biogen position peaked at $2.47B in Q1 2015.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.